Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple m...
Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Background
CD38 has been established as an important therapeutic target for multiple myeloma (MM), for which two CD38 antibodies are currently approved—daratumumab and isatuximab. CD38 is an ectoenzyme that degrades NAD and its precursors and is involved in the production of adenosine and other metabolites.
Aim
Among the various mechanisms...
Alternative Titles
Full title
Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_11c9e5f0da7846b4a4ba574aa7ba86ce
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_11c9e5f0da7846b4a4ba574aa7ba86ce
Other Identifiers
ISSN
2045-7634
E-ISSN
2045-7634
DOI
10.1002/cam4.6619
